The differentiation of propafenone from other class Ic agents, focusing on the effect on ventricular response rate attributable to its beta-blocking action

European Journal of Clinical Pharmacology

Volumn 51, Issue 3-4, 1996, Pages 199-208

  Faber, T S ^a,b   Camm, A J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

adrenoceptor blockade; antiarrhythmic agents; flecainide; Ic agents; propafenone; encaimide; ventricular response

Indexed keywords

BETA ADRENERGIC RECEPTOR; PROPAFENONE; PROPRANOLOL; SODIUM CHANNEL;

DRUG STRUCTURE; ELECTROPHYSIOLOGY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; STEREOISOMERISM;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; HEART; HEART VENTRICLES; HUMANS; PROPAFENONE; SODIUM CHANNEL BLOCKERS;

EID: 0030444791     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050184     Document Type: Review

References (103)

1. Delgado C, Tamargo J, Tejerina T (1985) Electrophysiological effects of propafenone in untreated and propafenone-pretreated guinea-pig atrial and ventricular muscle fibres. Br J Pharmacol 86:765-775
2. Tamargo J, Delgado C (1985) Electrophysiological effects of propafenone on isolated guinea-pig ventricular muscle and sheep Purkinje fibres. Eur J Pharmacol 118:331-340
3. Thompson KA, Iansmith DH, Siddoway LA, Woosley RL, Roden DM (1988) Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje fibers. J Pharmacol Exp Ther 244:950-955
4. Malfatto G, Zaza A, Forster M, Sodowick B, Danilo P Jr, Rosen MR (1988) Electrophysiologic, inotropic and antiarrhythmic effects of propafenone, 5-hydroxypropafenone and N-depropylpropafenone. J Pharmacol Exp Ther 246:419-426
5. Dukes ID, Vaughan Williams EM (1984) The multiple modes of action of propafenone. Eur Heart J 5:115-125
6. max studies with propafenone and derivatives in mammalian ventricular myocardium. Pflügers Arch 39:199-209
7. Ledda F, Mantelli L, Manzini S, Amerini S, Mugelli A (1983) Electrophysiological and antiarrhythmic properties of propafenone in isolated cardiac preparations. J Cardiovasc Pharmacol 3:1162-1173
8. Vaughan Williams EM (1984) A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 24:129-147
9. Vaughan Williams EM (1992) The relevance of cellular to clinical electrophysiology in classifying antiarrhythmic actions. J Cardiovasc Pharmacol 20 [Suppl 2]:S1-7
10. Abi Samra F (1989) The clinical use of class IC antiarrhythmic drugs. Louisiana State Med Soc 141:27-31
11. Härtel G (1985) Efficacy of oral propafenone in chronic ventricular arrhythmias: a placebo controlled crossover exercise study. Eur Heart J 6:123-129
12. Zoble RG, Kirsten EB, Brewington J (1989) Pharmacokinetic and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia. Propafenone Research Group. Clin Pharmacol Ther 45:535-541
13. Connolly SJ, Kates RE, Lebsack CS, Harrison DC, Winkle RA (1983) Clinical pharmacology of propafenone. Circulation 68:589-596
14. de Soyza N, Terry L, Murphy ML et al. (1984) Effect of propafenone in patients with stable ventricular arrhythmias. Am Heart J 108:285-289
15. Shen EN, Sung RJ, Morady F et al. (1984) Electrophysiologic and haemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia. J Am Coll Cardiol 3:1291-1297
16. Podrid PJ, Lown B (1984) Propafenone: a new agent for ventricular arrhythmia. J Am Coll Cardiol 4:117-125
17. Donovan KD, Dobb GJ, Coombs LJ et al. (1991) Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide. Am J Cardiol 67:137-141
18. Camm AJ, Hellestrand KJ, Nathan AW, Bexton RS (1985) Clinical usefulness of flecainide acetate in the treatment of paroxysmal supraventricular arrhythmias. Drugs 29 [Suppl 4]: 7-13
19. Markel ML, Prystowsky EN, Heger JJ, Miles WM, Fineberg N, Zipes DP (1986) Encainide for treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome. Am J Cardiol 58:41C-48C
20. Shen EN, Keung E, Huycke E, (1986) Intravenous propafenone for termination of reentrant supraventricular tachycardia. A placebo-controlled, randomized, double-blind, crossover study. Ann Intern Med 105: 655-661
21. Hammill SC, McLaran CJ, Wood DL, Osborn MJ, Gersh BJ, Holmes DR, Jr (1987) Double-blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia. J Am Coll Cardiol 9:1364-1368
22. Ludmer PL, McGowan NE, Antman EM, Friedman PL (1987) Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. J Am Coll Cardiol 9:1357-1363
23. Bryson HMA, Palmer KJ, Langtry HD, Fitton A (1993) Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. Drugs 45:85-130
24. Vita JA, Friedman PL, Cantillon C, Amman EM (1989) Efficacy of intravenous propafenone for the acute management of atrial fibrillation. Am J Cardiol 63:1275-1278
25. Bellandi F, Cantini F, Pedone T, Dabizzi RP, Palchetti R (1993) Efficacia del propafenone e dell'amiodarone endovena nella conversione della fibrillazione atriale recente. Follow-up di anno con trattamento orale. G Ital Cardiol 23: 261-271
26. Lee JH, Rosen MR (1991) Use-dependent actions and effects on trans-membrane action potentials of flecainide, encainide, and ethmozine in canine Purkinje fibres. J Cardiovasc Pharmacol 18:285-292
27. Crozier IG, Ikram H, Kenealy M, Levy L (1987) Flecainide acetate for conversion of acute supraventricular tachycardia to sinus rhythm. Am J Cardiol 59:607-609
28. Crijns HJ, van Wijk LM, van Gilst WH, Kingma JH, van Gelder IC, Lie KI (1988) Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. Eur Heart J 9:634-638
29. Coumel P, Leclercq JF, Assayag P, Maisonblanche P, Cauchemez B (1984) Effet anti-arythmique de la propafenone per os. A propos de 70 observations. Arch Mal Coeur Vaiss 77:1370-1382
30. Bianconi L, Boccadamo R, Pappalardo A, Gentili C, Pistolese M (1989) Effectiveness of intravenous propafenone for conversion of at rial fibrillation and flutter of recent onset. Am J Cardiol 64:335-338
31. Breithardt G, Borggrefe M, Wiebringhaus E, Seipel L (1984) Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. Am J Cardiol 54:29D-39D
32. Capucci A, Boriani G, Rubino I, Della Casa S, Sanguinetti M, Magnani B (1994) A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol 43:305-313
33. Goy JJ, Metrailler JC, Humair L, de Torrente A (1991) Restoration of sinus rhythm in atrial fibrillation of recent onset using intravenous propafenone. Am Heart J 122: 1788-1790
34. Kim SS, Smith P, Ruffy R (1988) Treatment of atrial tachyarrhythmias and preexcitation syndrome with flecainide acetate. Am J Cardiol 62:29D-34D
35. Kingma JH, Suttorp MJ (1992) Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. Am J Cardiol 70:56A-61A
36. Margheri M, Fradella G, Maioli M et al. (1992) Efficacia del propafenone e.v. e per os nel trattamento ambulatoriale della fibrillazione atriale di recente insorgenza. G Ital Cardiol 22:257-265
37. Nathan AW, Camm AJ, Bexton RS, Hellestrand KJ (1987) Intravenous flecainide acetate for the clinical management of paroxysmal tachycardias. Clin Cardiol 10:317-322
38. Pietersen AH, Hellemann H (1991) Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group. Am J Cardiol 67:713-717
39. Pritchett EL, McCarthy EA, Wilkinson WE (1991) Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med 114:539-544
40. Prystowsky EN, Klein GJ, Rinkenberger RL, Heger JJ, Naccarelli GV, Zipes DP (1984) Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome. Circulation 69:278-287
41. O'Nunain S, Carrait CJ, Linker NJ, Gill J, Ward DE, Camm AJ (1991) A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol 14:2028-2034
42. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321: 406-412
43. Vaughan Williams EM (1991) Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial. J Clin Pharmacol 31:123-135
44. Funck-Brentano C, Kroemer HK, Lee JT, Roden DM (1990) Propafenone. N Engl J Med 322:518-525
45. Inama G, Furlanello F, Braito G, Guarnerio M, Vergara G (1991) Test elettrofarmacologici con farmaci della classe I C nella tachicardia porossistica sopraventricolare reciprocante: il risultato negativo di un farmaco e predittivo di inefficacia per altri farmaci della stessa classe? G Ital Cardiol 21: 131-138
46. McLeod AA, Stiles GL, Shand DG (1984) Demonstration of beta adrenoceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylate cyclase activation studies. J Pharmacol Exp Ther 228: 461-466
47. Muller-Peltzer H, Greger G, Neugebauer G, Hollmann M (1983) Beta-blocking and electrophysiological effects of propafenone in volunteers. Eur J Clin Pharmacol 25:831-833
48. Malfatto G, Pessano P, Zaza A, Schwartz PJ (1993) Experimental evidence for beta adrenergic blocking properties of propafenone and for their potential clinical relevance. Eur Heart J 14:1253-1257
49. Ledda F, Mantelli L (1984) Proprieta elettrofisiologiche ed antiaritmiche del propafenone desumibili studi sperimentali in vitro. G Ital Cardiol 14:279-284
50. Lee JT, Kroemer HK, Silberstein DJ, et al.(1990) The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Enal J Med 322:1764-1768
51. Kroemer HK, Funck-Brentano C, Silberstein DJ, et al. (1989) Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation 79:1068-1076
52. Hollmann M, Brode E, Holtz D, (1983) Investigation on the pharmacokinetics in man. Arzneimittelforschung 33: 763-770
53. Gillis AM, Yee YG, Kates TE (1985) Binding of antiarrhythmic drug to purified human alpha 1-acid glycoprotein. Biochem Pharmacol 34:4279-4282
54. von Philipsborn G, Gries J, Hofmann HP et al. (1984) Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone. Arzneimittelforschung 34:1489-1497
55. Siddoway LA, Thompson KA, McAllister CB et al. (1987) Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 75:785-791
56. Funk-Brentano C, Kroemer HK, Pavlou H, Woosly RL, Roden DM (1989) Genetically determined interaction between propafenone and low-dose quinidine: role of active metabolites in modulating net drug effect. Br J Clin Pharmacol 27:435-444
57. Brode E, Müller Peltzer H, Hollmann R (1988) Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration in man. Methods Find Exp Clin Pharmacol 10:717-727
58. Kates RE, Yee YG, Winkle RA (1985) Metabolic cumulation during chronic propafenone dosing in arrhythmia. Clin Pharmacol Ther 9:610-614
59. Hege HG, Hollmann M, Kavmeier S et al. (1984) The metabolic fate of 3H-labelled propafenone in man. Eur J Drug Metab Pharmacokinet 9:41-55
60. Manz M, Steinbeck G, Luderitz B (1985) Usefulness of programmed stimulation in predicting efficacy of propafenone in long-term antiarrhythmic therapy for paroxysmal supraventricular tachycardia. Am J Cardiol 56:593-597
61. Honjo H, Watanabe T, Kamiya K, Kodama I, Toyama J (1989) Effects of propafenone on electrical and mechanical activities of single ventricular myocytes isolated from guinea-pig hearts. Br J Pharmacol 97:731-738
62. Burnett DM, Gal J, Zahniser NR, Nies AS (1988) Propafenone interacts stereoselectively with beta 1- and beta 2-adrenergic receptors. J Cardiovasc Pharmacol 12:615-619
63. Drici MD, Sbirrazzuoli V, Garraffo R, Wajman A, Morand P, Lapalus P (1989) Effect of propafenone hydrochloride on lymphocyte membrane beta 2 adrenoceptors in ventricular arrhythmias. Am J Cardiol 64:671-674
64. Paietta E, Poch G, Kukovetz WR (1977) Analyse der Beta-Blocker Wirkung von Propafenon (SA79). In: Hochrein H, Hapke HJ, Beck OA (eds), Fischer, Stuttgart pp 20-28
65. Hill MR, Gotz VP, Harman E, McLeod I, Hendeles L (1986) Evaluation of the asthmogenicity of propafenone, a new antiarrhythmic drug. Comparison of spirometry with methacholine challenge. Chest 90:698-702
66. Manolis AS, Katsaros C, Cokkinos DV (1992) Electrophysiological and electropharmacological studies in pre-excitation syndromes: results with propafenone therapy and isoproterenol infusion testing. Eur Heart J 13: 1489-1495
67. Auricchio A (1992) Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection. Am Heart J 124: 932-937
68. Cleaveland CR, Rangno RE, Shand DG (1972) A standardized isoproterenol sensitivity test. The effects of sinus arrhythmia, atropine, and propranolol. Arch Intern Med 130: 47-52
69. Cheriex EC, Krijne R, Brugada P, Heymeriks J, Wellens HJ (1987) Lack of clinically significant beta-blocking effect of propafenone. Eur Heart J 8:53-56
70. Malliani A, Pagani M, Lombardi F, Cerutti S (1991) Cardiovascular neural regulation explored in the frequency domain. Circulation 84:482-492
71. Bekheit S, Tangella M, El-Sakr A, Rasheed Q, Craelius W, El-Sharif N (1990) Use of heart rate spectral analysis to study the effects of calcium channel blockers on sympathetic activity after myocardial infarction. Am Heart J 119:79-85
72. Cook JR, Bigger jr, Kleiger RE, Fleiss JL, Steinman RC, Rolnitzky LM (1991) Effect of atenolol and diltiazem on heart period variability in normal persons. J Am Coll Cardiol 17:480-484
73. Lombardi F, Torzillo D, Sandrone G (1992) Beta-blocking effect of propafenone based on spectral analysis of heart rate variability. Am J Cardiol 70:1028-1034
74. Mannino MM, Mehta D, Gomes JA (1994) Current treatment options for paroxysmal supraventricular tachycardia. Am Heart J 127:475-480
75. Santinelli V, de Paola M, Turco P(1989) Paroxysmal supraventricular tachycardia: experience with propafenone. Angiology 40:563-568
76. Botto GL, Bonini W, Broffoni T (1994) Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm. Pacing Clin Electrophysiol 17:2114-2117
77. Cobbe SM (1994) A randomized placebo controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachyarrhythmias [abstract]. J Am Coll Cardiol Special Issue(Feb): 251A
78. Chimienti M, Casadei G (1994) Flecainide versus propafenone in the prevention of paroxysmal atrial fibrillation. A long term randomised multi-centre study [abstract]. J Am Coll Cardiol Special Issue (Feb.): 91A
79. Tisi G, Annoni P, Baroffio R, Cazzaniga L et al. (1987) Randomised placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery. J Am Coll Cardiol 10:1145-1148
80. Proclemer A, Miorelli M, Pavan A et al. (1994) Intraveneous propafenone in paroxysmal atrial fibrillation: a randomised, placebo controlled, double-blind, multi-centre clinical trial [abstract]. J Am Coll Cardiol Special Issue (Feb.): 368A
81. Berti S, Trianni G, Cataldo P et al. (1994) Low dose propafenone versus deslanoside for the out-of-hospital treatment of paroxysmal atrial fibrillation. A single blind study [abstract]. Pacing Clin Electrophysiol 17:764
82. Gentili C, Giordano F, Alois A, Massa E, Bianconi L (1992) Efficacy of intravenous propafenone in acute atrial fibrillation complicating open-heart surgery. Am Heart J 123: 1225-1228
83. Leather RA, Klein GJ, Murdoch C, Yee R, Leitch JW (1994) The inefficacy of intravenous propafenone for rate control in atrial fibrillation. Can J Cardiol 10:433-438
84. Camm AJ, Katritsis D, Nunain SO (1992) Effects of flecainide on atrial electrophysiology in the Wolff - Parkinson - White syndrome. Am J Cardiol 70:33A-37A
85. Vignati G, Mauri L, Figini A (1993) The use of propafenone in the treatment of tachyarrhythmias in children. Eur Heart J 14:546-550
86. Musto B, A DO, Cavallaro C, Musto A (1988) Electrophysiological effects and clinical efficacy of propafenone in children with recurrent paroxysmal supraventricular tachycardia. Circulation 78:863-869
87. Reimer A, Paul T, Kallfelz HC (1991) Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias. Am J Cardiol 68:741-744
88. Moak JP, Smith RT, Garson A, Jr (1987) Newer antiarrhythmic drugs in children. Am Heart J 113:179-185
89. Paul T, Reimer A, Janousek J et al. (1992) Efficacy and safety of propafenone in congenital junctional ectopic tachycardia. J Am Coll Cardiol 20:911-914
90. Abdollah H, Brugada P, Green M, Wehr M, Wellens HJ (1984) Clinical efficacy and electrophysiologic effects of intravenous and oral encainide in patients with accessory atrioventricular pathways and supraventricular arrhythmias. Am J Cardiol 54:544-549
91. Niazi I, Naccarelli G, Dougherty A, Rinkenberger R, Tchou P, Akhtar M (1989) Treatment of atrioventricular node reentrant tachycardia with encainide: reversal of drug effect with isoproterenol. J Am Coll Cardiol 13:904-910
92. Manolis AS, Estes NAD (1989) Reversal of electrophysiologic effects of flecainide on the accessory pathway by isoproterenol in the Wolff-Parkinson-White syndrome. Am J Cardiol 64:194-198
93. Akhtar M, Niazi I, Naccarelli GV et al. (1988) Role of adrenergic stimulation by isoproterenol in reversal of effects of encainide in supraventricular tachycardia. Am J Cardiol 62:45L-49L
94. Helmy I, Scheinman MM, Herre JM, Sharkey H, Griffin JC (1990) Electrophysiologic effects of isoproterenol in patients with atrioventricular reentrant tachycardia treated with flecainide. J Am Coll Cardiol 16:1649-1655
95. Brembilla-Perrot B, Admant P, Le Helloco A, Pernot C (1985) Loss of efficacy of flecainide in the Wolff-Parkinson-White syndrome after isoproterenol administration. Eur Heart J 6: 1074-1078
96. Zuanetli G, Latini R, Neilson JM, Schwartz PJ, Ewing DJ (1991) Heart rate variability in patients with ventricular arrhythmias: effect of antiarrhythmic drugs. Antiarrhythmic Drug Evaluation Group (ADEG). J Am Coll Cardiol 17:604-612
97. Falk RH (1989) Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 111:107-111
98. Kowey PR, Stohler JL, Friehling TD, Marinchak RA (1991) Propafenone in the treatment of patients with malignant ventricular tachyarrhythmias. Can J Cardiol 7:175-180
99. Podrid PJ, Cytryn R, Lown B (1984) Propafenone: noninvasive evaluation of efficacy. Am J Cardiol 54:53D-59D
100. Ravid S, Podrid PJ, Novrit B (1987) Safety of long-term propafenone therapy for cardiac arrhythmia-experience with 774 patients. J Electrophysiol 1:580-590
101. Hernandez M, Reder RF, Murinchak RA, Rials SJ, Kowey PR (1991) Propafenone for malignant ventricular arrhythmia: an analysis of the literature. Am Heart J 121:1178-1184
102. Pritchett ELC, Wilkinson WE, Clair WK, McCarthy EA (1993) Comparison of mortality in patients treated with propafenone to those treated with a variety of antiarrhythmic drugs for supraventricular arrhythmias. Am J Cardiol 72:108-110
103. Myerburg RJ, Kessler KM, Cox MM et al. (1989) Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol. Circulation 80:1571-1579